This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/national-drug-code-directory/
n6http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n23http://www.rxlist.com/cgi/generic/
n11http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/wikipedia/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB01280/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01280
rdf:type
n3:Drug
n3:description
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity.
n3:dosage
n14:271B6298-363D-11E5-9242-09173F13E4C5 n14:271B6299-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Buie LW, Epstein SS, Lindley CM: Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007 Sep;29(9):1887-99. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18035189 # DeAngelo DJ: Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19825456 # Roecker AM, Allison JC, Kisor DF: Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol. 2006 Aug;2(4):441-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16922610 # Sanford M, Lyseng-Williamson KA: Nelarabine. Drugs. 2008;68(4):439-47. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18318562 # Reilly KM, Kisor DF: Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20616909 # Cooper TM: Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag. 2007 Dec;3(6):1135-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18516261 # Curbo S, Karlsson A: Nelarabine: a new purine analog in the treatment of hematologic malignancies. Rev Recent Clin Trials. 2006 Sep;1(3):185-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18473971 # Sigalas P, Tourvas AD, Moulakakis A, Pangalis G, Kontopidou F: Nelarabine induced complete remission in an adult with refractory T-lineage acute lymphoblastic leukemia: A case report and review of the literature. Leuk Res. 2009 Jul;33(7):e61-3. Epub 2009 Jan 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19157550 # Gandhi V, Keating MJ, Bate G, Kirkpatrick P: Nelarabine. Nat Rev Drug Discov. 2006 Jan;5(1):17-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16485343
n3:group
approved investigational
n3:halfLife
Nelarabine and ara-G are rapidly eliminated from plasma with a half-life of approximately 30 minutes and 3 hours.
n3:indication
For the treatment of pediatric and adult patients with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
owl:sameAs
n6:DB01280 n20:DB01280
dcterms:title
Nelarabine
adms:identifier
n16:PA164752425 n17:Nelarabine n21:DB01280 n22:D05134 n24:2280207 n25:46506325 n26:0007-4401-06 n27:3011155
n3:mechanismOfAction
Once nelarabine is metabolized into ara-GTP, the metabolite accumulates in leukemic blasts and incorporates into DNA to exert its S phase-specific cytotoxic effects, leading to the induction of fragmentation and apoptosis. Ara-GTP competes with endogenous deoxyGTP (dGTP) for incorporation into DNA. Once ara-GTP is incorporated at the 3' end of DNA, further DNA elongation is inhibited, which signals apoptosis and leads to cellular destruction. Additional cytotoxic activities may exist, but these are not fully understood.
n3:packager
n19:271B6296-363D-11E5-9242-09173F13E4C5
n3:patent
n11:5492897 n11:5424295
n3:routeOfElimination
Excretion: Nelarabine and ara-G are partially eliminated by the kidneys.
n3:synonym
Nelzarabine Arranon GW-506U78 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine
n3:toxicity
A single IV dose of 4,800 mg/m^2 was lethal in monkeys, and was associated with CNS signs including reduced/shallow respiration, reduced reflexes, and flaccid muscle tone. It is anticipated that overdosage would result in severe neurotoxicity (possibly including paralysis, coma), myelosuppression, and potentially death.
n3:proteinBinding
Nelarabine and ara-G are not substantially bound to human plasma proteins (<25%) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 mM.
n12:hasConcept
n13:M0359430
foaf:page
n8:nelarabine.html n23:arranon.htm
n3:IUPAC-Name
n4:271B629E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B62A4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B62A3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B62A0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B62A1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B62A2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B62B4-363D-11E5-9242-09173F13E4C5 n4:271B629C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B62B6-363D-11E5-9242-09173F13E4C5 n4:271B629D-363D-11E5-9242-09173F13E4C5 n4:271B629A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B629B-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:L01BB07
n3:H-Bond-Acceptor-Count
n4:271B62AA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B62AB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B62A5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B62A6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B62A8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B62A7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B62A9-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
121032-29-9
n3:clearance
* 197  +/-  189 L/h/m2 [Adult patients with refractory leukemia or lymphoma receiving doses of 199 to 2,900 mg/m2] * 259  +/-  409 L/h/m2 [Pediatric patients with refractory leukemia or lymphoma receiving doses of 104 to 2,900 mg/m2]
n3:containedIn
n18:271B6297-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B62B0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B62B2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B62B3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B62B5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B62AF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B62AE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B62B1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B629F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B62AC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B62AD-363D-11E5-9242-09173F13E4C5